---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015527"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:34:17.879110+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia Q2 NUPLAZID sales $134.6M (+17% YoY); NDA filed for trofinetide in Rett syndrome

## Summary
- Q2 net loss $34.0M ($0.21/share) vs $43.9M loss in Q2 2021; six-month loss $147.1M.
- R&D expense $75.6M vs $56.9M YoY; SG&A $89.9M vs $96.8M on lower promo costs.
- NDA submitted to FDA for trofinetide for Rett syndrome; CRL received for pimavanserin in Alzheimer's psychosis.
- Discontinued development of ACP-044 (pain) and ACP-319 (M1 PAM) based on data review.
- 2022 NUPLAZID revenue guidance narrowed to $510-540M from $510-560M; R&D guidance reduced.

## SEC filing metadata
- accession: 0000950170-22-015527
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017022015527/0000950170-22-015527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017022015527/acad-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015527
- JSON: https://secwatch.observer/filing/0000950170-22-015527.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.